Engineered Antimicrobial Peptides Block SARS-CoV-2 Entry by Targeting ACE2 and TMPRSS2
Computationally mutated antimicrobial peptides showed ability to inhibit ACE2, TMPRSS2, and spike protein interactions, presenting a peptide-based approach to blocking SARS-CoV-2 cell entry.
Quick Facts
What This Study Found
Computationally designed antimicrobial peptide mutants showed potential to inhibit ACE2, TMPRSS2, and spike protein interactions, targeting multiple steps of SARS-CoV-2 cell entry.
Key Numbers
Four key receptors were targeted: ACE2, TMPRSS2, GRP78, and AT1R. Multiple databases were used including RCSB PDB, StraPep, and PhytAMP.
How They Did This
Computational mutagenesis of antimicrobial peptides. Molecular docking and binding affinity analysis against ACE2, TMPRSS2, and spike protein. Stability and interaction characterization.
Why This Research Matters
Viral mutations can evade vaccines and drugs targeting a single protein. Peptides that block multiple entry points simultaneously would be much harder for the virus to escape, providing more durable antiviral protection.
The Bigger Picture
Antimicrobial peptides that also have antiviral properties represent a dual-defense approach. Engineering them to target multiple viral entry mechanisms creates peptide-based antivirals that could complement vaccines and address future pandemic threats.
What This Study Doesn't Tell Us
Computational study — predictions need experimental validation. In silico binding does not guarantee in vivo antiviral activity. Manufacturing and delivering multi-target peptides is challenging.
Questions This Raises
- ?Do these computationally designed peptides block SARS-CoV-2 entry in cell culture experiments?
- ?Would multi-target peptide antivirals work against SARS-CoV-2 variants and future coronaviruses?
- ?Can these peptides be delivered as nasal sprays for prophylactic antiviral protection?
Trust & Context
- Key Stat:
- Triple blockade Engineered peptides target ACE2, TMPRSS2, and spike protein simultaneously, making viral escape through mutation more difficult
- Evidence Grade:
- Preliminary evidence: computational design study requiring experimental validation for antiviral activity.
- Study Age:
- Published in 2024. Addresses ongoing need for broad-spectrum antiviral strategies.
- Original Title:
- Investigation of the mutated antimicrobial peptides to inhibit ACE2, TMPRSS2 and GRP78 receptors of SARS-CoV-2 and angiotensin II type 1 receptor (AT1R) as well as controlling COVID-19 disease.
- Published In:
- Journal of biomolecular structure & dynamics, 43(4), 1641-1664 (2025)
- Database ID:
- RPEP-09747
Evidence Hierarchy
Frequently Asked Questions
Can peptides fight viruses?
Yes — antimicrobial peptides can have antiviral properties by blocking viral entry into cells or disrupting viral membranes. These engineered peptides target three proteins involved in SARS-CoV-2 entry, potentially blocking infection at multiple steps.
Why target three proteins instead of one?
Viruses can mutate to evade drugs targeting a single protein. By designing peptides that block three different entry points (ACE2, TMPRSS2, and spike), the virus would need to mutate all three simultaneously to escape — making resistance much less likely.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09747APA
Abedi Dorcheh, Fatemeh; Balmeh, Negar; Hejazi, Seyed Hossein; Allahyari Fard, Najaf. (2025). Investigation of the mutated antimicrobial peptides to inhibit ACE2, TMPRSS2 and GRP78 receptors of SARS-CoV-2 and angiotensin II type 1 receptor (AT1R) as well as controlling COVID-19 disease.. Journal of biomolecular structure & dynamics, 43(4), 1641-1664. https://doi.org/10.1080/07391102.2023.2292307
MLA
Abedi Dorcheh, Fatemeh, et al. "Investigation of the mutated antimicrobial peptides to inhibit ACE2, TMPRSS2 and GRP78 receptors of SARS-CoV-2 and angiotensin II type 1 receptor (AT1R) as well as controlling COVID-19 disease.." Journal of biomolecular structure & dynamics, 2025. https://doi.org/10.1080/07391102.2023.2292307
RethinkPeptides
RethinkPeptides Research Database. "Investigation of the mutated antimicrobial peptides to inhib..." RPEP-09747. Retrieved from https://rethinkpeptides.com/research/abedi-2025-investigation-of-the-mutated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.